The prognosis of patients with glioblastoma (GBM) remains dismal, with a median survival of approximately 15 months. Current preclinical GBM models are limited by the lack of a "normal" human microenvironment and the inability of many tumor cell lines to accurately reproduce GBM biology. To address these limitations, we have established a model system whereby we can retro-engineer patient-specific GBMs using patient-derived glioma stem cells (GSCs) and human embryonic stem cell (hESC)-derived cerebral organoids. Our cerebral organoid glioma (GLICO) model shows that GSCs home toward the human cerebral organoid and deeply invade and proliferate within the host tissue, forming tumors that closely phenocopy patient GBMs. Furthermore, cerebral organoid tumors form rapidly and are supported by an interconnected network of tumor microtubes that aids in the invasion of normal host tissue. Our GLICO model provides a system for modeling primary human GBM ex vivo and for high-throughput drug screening.
Keywords: brain tumors; cancer stem cells; cerebral organoids; glioblastoma; glioma; glioma stem cells; human embryonic stem cells; stem-cell-based disease models; tissue engineering; tumor microtubes.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
DECLARATION OF INTERESTS
The authors declare no competing interests.
Spontaneous Glioblastoma Spheroid Infiltration of Early-Stage Cerebral Organoids Models Brain Tumor InvasionB da Silva et al. SLAS Discov 23 (8), 862-868. PMID 29543559.Organoid methodology provides a platform for the ex vivo investigation of the cellular and molecular mechanisms underlying brain development and disease. The high-grade b …
A Three-Dimensional Organoid Culture System Derived From Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In VivoCG Hubert et al. Cancer Res 76 (8), 2465-77. PMID 26896279.Many cancers feature cellular hierarchies that are driven by tumor-initiating cancer stem cells (CSC) and rely on complex interactions with the tumor microenvironment. St …
Patient-Derived Glioma Models: From Patients to Dish to AnimalsCC da Hora et al. Cells 8 (10). PMID 31574953. - ReviewGlioblastoma (GBM) is the most common and malignant primary brain tumor in adults associated with a poor survival. Current standard of care consists of surgical resection …
Resveratrol Targeting of AKT and p53 in Glioblastoma and Glioblastoma Stem-Like Cells to Suppress Growth and InfiltrationPA Clark et al. J Neurosurg 126 (5), 1448-1460. PMID 27419830.OBJECTIVE Glioblastoma multiforme (GBM) is an aggressive brain cancer with median survival of less than 2 years with current treatment. Glioblastomas exhibit extensive in …
Cancer Stem Cells in Glioblastoma--Molecular Signaling and Therapeutic TargetingZ Huang et al. Protein Cell 1 (7), 638-55. PMID 21203936. - ReviewGlioblastomas (GBMs) are highly lethal primary brain tumors. Despite current therapeutic advances in other solid cancers, the treatment of these malignant gliomas remains …
Cited by 4 PubMed Central articles
Studying Human Neurodevelopment and Diseases Using 3D Brain OrganoidsA Tian et al. J Neurosci 40 (6), 1186-1193. PMID 32024767.In vitro differentiation of pluripotent stem cells provides a systematic platform to study development and disease. Recent advances in brain organoid technology ha …
iPSCs-Based Neural 3D Systems: A Multidimensional Approach for Disease Modeling and Drug DiscoveryG Costamagna et al. Cells 8 (11). PMID 31739555. - ReviewInduced pluripotent stem cells (iPSCs)-based two-dimensional (2D) protocols have offered invaluable insights into the pathophysiology of neurological diseases. However, t …
Past, Present, and Future of Brain Organoid TechnologyB Koo et al. Mol Cells 42 (9), 617-627. PMID 31564073. - ReviewBrain organoids are an exciting new technology with the potential to significantly change our understanding of the development and disorders of the human brain. With step …
Preclinical Modelling of PDA: Is Organoid the New Black?S D'Agosto et al. Int J Mol Sci 20 (11). PMID 31195689. - ReviewPancreatic ductal adenocarcinoma (PDA) is a malignancy of the exocrine pancreas with the worst prognosis among all solid tumours, and soon to become the second leading ca …